Wave Life Sciences Ltd.
$7.58
▲
6.59%
2026-04-21 10:20:00
wavelifesciences.com
NGM: WVE
Explore Wave Life Sciences Ltd. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.43 B
Current Price
$7.58
52W High / Low
$21.73 / $5.02
Stock P/E
—
Book Value
$2.76
Dividend Yield
—
ROCE
-39.63%
ROE
-54.97%
Face Value
—
EPS
$-1.21
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
317
Beta
-1.32
Debt / Equity
3.38
Current Ratio
6.47
Quick Ratio
6.47
Forward P/E
-5.58
Price / Sales
31.64
Enterprise Value
$775.24 M
EV / EBITDA
-3.66
EV / Revenue
18.14
Rating
Strong Buy
Target Price
$25.73
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Satellos Bioscience Inc. | $7.83 | — | $248.1 M | — | -95.23% | -66.37% | $18.98 / $6.24 | $1.8 |
| 2. | Cue Biopharma, Inc. | $0.85 | — | $82.97 M | — | -92.35% | -121.11% | $1.03 / $0.17 | $0.27 |
| 3. | Passage Bio, Inc. | $6.25 | — | $37.44 M | — | -110.08% | -1.14% | $20 / $5.12 | $5.89 |
| 4. | Kura Oncology, Inc. | $9.78 | — | $863.87 M | — | -48.86% | -94.82% | $12.49 / $5.45 | $1.98 |
| 5. | Revolution Medicines, Inc. | $143.09 | — | $30.24 B | — | -57.28% | -58.07% | $155.7 / $34 | $8.28 |
| 6. | Enlivex Ltd. | $0.88 | — | $207.92 M | — | -0.65% | 1.26% | $2.1 / $0.66 | $8.15 |
| 7. | Silence Therapeutics plc | $7.93 | — | $349.74 M | — | -76.17% | -90.27% | $2.6 / $0.5 | $1.32 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 17.25 M | 7.61 M | 8.7 M | 9.18 M | 83.75 M | — |
| Operating Profit | -56.47 M | -56.35 M | -52.76 M | -49.8 M | 22.97 M | — |
| Net Profit | -53.18 M | -53.85 M | -50.47 M | -46.88 M | 29.25 M | — |
| EPS in Rs | -0.28 | -0.29 | -0.27 | -0.25 | 0.16 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 42.73 M | 108.3 M | 113.31 M | 3.65 M |
| Operating Profit | -215.38 M | -110.4 M | -68 M | -162.72 M |
| Net Profit | -204.38 M | -97.01 M | -57.51 M | -161.82 M |
| EPS in Rs | -1.09 | -0.52 | -0.31 | -0.86 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 638.5 M | 352.21 M | 274.95 M | 146.39 M |
| Total Liabilities | 120.14 M | 142.69 M | 235.32 M | 191.48 M |
| Equity | 518.36 M | 209.51 M | 39.63 M | -45.09 M |
| Current Assets | 614.81 M | 320.39 M | 235.37 M | 98.54 M |
| Current Liabilities | 95.06 M | 110.95 M | 186.44 M | 71.52 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -187.49 M | -151.03 M | -19.43 M | -127.78 M |
| Investing CF | -0.72 M | -0.94 M | -1.11 M | -1.25 M |
| Financing CF | 488.24 M | 253.89 M | 132.53 M | 67.19 M |
| Free CF | -188.21 M | -151.96 M | -20.55 M | -129.14 M |
| Capex | -0.72 M | -0.94 M | -1.11 M | -1.36 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Revenue Growth % | -60.55% | -4.42% | 3005.1% | — |
| Earnings Growth % | -110.68% | -68.67% | 64.46% | — |
| Profit Margin % | -478.33% | -89.57% | -50.76% | -4434.72% |
| Operating Margin % | -504.09% | -101.94% | -60.01% | -4459.3% |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -483.37% | -93.94% | -51.89% | -4182.13% |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.